In North America and Europe, TS prophylaxis prevents Pneumocystis jirovecii pneumonia (PCP) and toxoplasmosis, and is discontinued after the CD4 cell count reaches 200/mm3. The gene discussed is CD4; the disease is pneumocystosis.